Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvaCoat Mx sinus gel in chronic rhinosinusitis without nasal polyps
NL-OMON32392Phase 2Active, not recruiting
- Sponsor
- Carbylan Therapeutics
- Start
- Oct 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AdvaCoat and triamcinolone acetonide in chronic rhinosinusitis (CRS) (4 arms), sponsored by Carbylan Therapeutics. Primary endpoint: Safety. Started Oct 2008; status: active, not recruiting.
02
Drugs
AdvaCoattriamcinolone acetonide
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NL-OMON32392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32392.